{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:24:38Z","timestamp":1790267078708,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T00:00:00Z","timestamp":1597017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondi per la Ricerca Locale Universit\u00e0 di Torino 2018","award":["RILO 2018"],"award-info":[{"award-number":["RILO 2018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The impact of patient\u2019s characteristics on glucocorticoid (GC) replacement therapy in adrenal insufficiency (AI) is poorly evaluated. Aims of this study were to assess the influence of sex and body weight on GC dosing and to describe the choice of GC in AI of different etiologies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively evaluated hydrocortisone (HC) equivalent total daily dose (HC-TDD) and per-kg-daily dose (HC-KDD) in 203 patients (104 primary AI [pAI], 99 secondary AI [sAI]) followed up for\u2009\u2265\u200912\u00a0months. They were treated with HC, modified-release HC (MRHC) or cortisone acetate (CA) and fludrocortisone acetate (FCA) in pAI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>At baseline, CA was preferred both in pAI and sAI; at last visit, MRHC was most used in pAI (49%) and CA in sAI (73.7%). Comparing the last visit with baseline, in pAI, HC-TDD and HC-KDD were significantly lower (<jats:italic>p<\/jats:italic>\u2009=\u20090.04 and <jats:italic>p<\/jats:italic>\u2009=\u20090.006, respectively), while FCA doses increased during follow-up (<jats:italic>p<\/jats:italic>\u2009=\u20090.02). The reduction of HC-TDD and HC-KDD was particularly relevant for pAI women (<jats:italic>p<\/jats:italic>\u2009=\u20090.04 and <jats:italic>p<\/jats:italic>\u2009=\u20090.002, respectively). In sAI patients, no change of HC-KDD and HC-TDD was observed, and we found a correlation between weight and HC-TDD in males (<jats:italic>r<\/jats:italic> 0.35, <jats:italic>p<\/jats:italic>\u2009=\u20090.02).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our real-life study demonstrated the influence of etiology of AI on the type of GC used, a weight-based tailoring in sAI, a likely overdosage of GC treatment in pAI women at the start of treatment and the possibility to successfully increase FCA avoiding GC over-treatment. These observations could inform the usual clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-020-01386-3","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T21:02:54Z","timestamp":1597093374000},"page":"865-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["What factors have impact on glucocorticoid replacement in adrenal insufficiency: a real-life study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2883-6139","authenticated-orcid":false,"given":"S.","family":"Puglisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Tabaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cannav\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Ferrau\u2019","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ragonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Borretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pellegrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Dughera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Parisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Latina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Terzolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Reimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,10]]},"reference":[{"key":"1386_CR1","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(03)13492-7","volume":"361","author":"W Arlt","year":"2003","unstructured":"Arlt W, Allolio B (2003) Adrenal insufficiency. Lancet 361:1881\u20131893","journal-title":"Lancet"},{"key":"1386_CR2","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1007\/s40618-019-01079-6","volume":"42","author":"C Betterle","year":"2019","unstructured":"Betterle C, Presotto F, Furmaniak J (2019) Epidemiology, pathogenesis, and diagnosis of Addison's disease in adults. J Endocrinol Invest 42:1407\u20131433","journal-title":"J Endocrinol Invest"},{"key":"1386_CR3","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1530\/EJE-09-0170","volume":"161","author":"G Johannsson","year":"2009","unstructured":"Johannsson G, Bergthorsdottir R, Nilsson AG, Lennernas H, Hedner T et al (2009) Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur J Endocrinol 161:119\u2013130","journal-title":"Eur J Endocrinol"},{"key":"1386_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1210\/jc.2011-1926","volume":"97","author":"G Johannsson","year":"2012","unstructured":"Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P et al (2012) Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J Clin Endocrinol Metab 97:473\u2013481","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR5","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1007\/s12020-015-0681-z","volume":"51","author":"R Giordano","year":"2016","unstructured":"Giordano R, Guaraldi F, Marinazzo E, Fumarola F, Rampino A et al (2016) Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease. Endocrine 51:360\u2013368","journal-title":"Endocrine"},{"key":"1386_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S2213-8587(17)30398-4","volume":"6","author":"AM Isidori","year":"2018","unstructured":"Isidori AM, Venneri MA, Graziadio C, Simeoli C, Fiore D et al (2018) Effect of once-daily, modified-release hydrocortisone versus standard glucocorticoid therapy on metabolism and innate immunity in patients with adrenal insufficiency (DREAM): a single-blind, randomised controlled trial. Lancet Diabetes Endocrinol 6:173\u2013185","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1386_CR7","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.1210\/jc.2006-0076","volume":"91","author":"R Bergthorsdottir","year":"2006","unstructured":"Bergthorsdottir R, Leonsson-Zachrisson M, Od\u00e9n A, Johannsson G (2006) Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 91:4849\u20134853","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1365-2265.2008.03340.x","volume":"69","author":"S Bensing","year":"2008","unstructured":"Bensing S, Brandt L, Tabaroj F, Sj\u00f6berg O, Nilsson B et al (2008) Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 69:697\u2013704","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1386_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1530\/EJE-16-0657","volume":"176","author":"D Chantzichristos","year":"2017","unstructured":"Chantzichristos D, Persson A, Eliasson B, Miftaraj M, Franz\u00e9n S et al (2017) Mortality in patients with diabetes mellitus and Addison's disease: a nationwide, matched, observational cohort study. Eur J Endocrinol 176:31\u201339","journal-title":"Eur J Endocrinol"},{"key":"1386_CR10","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/cen.13609","volume":"89","author":"M Quinkler","year":"2018","unstructured":"Quinkler M, Ekman B, Zhang P, Isidori AM, Murray RD et al (2018) Mortality data from the European adrenal insufficiency registry-patient characterization and associations. Clin Endocrinol (Oxf) 89:30\u201335","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1386_CR11","doi-asserted-by":"publisher","first-page":"R231","DOI":"10.1530\/EJE-17-0154","volume":"177","author":"G Mazziotti","year":"2017","unstructured":"Mazziotti G, Formenti AM, Frara S, Roca E, Mortini P et al (2017) Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects. Eur J Endocrinol 177:R231\u2013R248","journal-title":"Eur J Endocrinol"},{"key":"1386_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1210\/er.2018-00097","volume":"39","author":"RS Hardy","year":"2018","unstructured":"Hardy RS, Zhou H, Seibel MJ, Cooper MS (2018) Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy. Endocr Rev 39:519\u2013548","journal-title":"Endocr Rev"},{"key":"1386_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1530\/EJE-09-0884","volume":"162","author":"S Hahner","year":"2010","unstructured":"Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D et al (2010) Epidemiology of adrenal crisis in chronic adrenal insufficiency: the need for new prevention strategies. Eur J Endocrinol 162:597\u2013602","journal-title":"Eur J Endocrinol"},{"key":"1386_CR14","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1210\/jc.2014-3191","volume":"100","author":"S Hahner","year":"2015","unstructured":"Hahner S, Spinnler C, Fassnacht M, Burger-Stritt S, Lang K et al (2015) High incidence of adrenal crisis in educated patients with chronic adrenal insufficiency: a prospective study. J Clin Endocrinol Metab 100:407\u2013416","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR15","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1365-2265.2004.02106.x","volume":"61","author":"PM Mah","year":"2004","unstructured":"Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A et al (2004) Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 61:367\u2013375","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1386_CR16","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/cen.12117","volume":"78","author":"M Debono","year":"2013","unstructured":"Debono M, Ross RJ (2013) What is the best approach to tailoring hydrocortisone dose to meet patient needs in 2012? Clin Endocrinol (Oxf) 78:659\u2013664","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1386_CR17","first-page":"379","volume":"102","author":"F Dalin","year":"2017","unstructured":"Dalin F, Nordling Eriksson G, Dahlqvist P, Hallgren \u00c5, Wahlberg J et al (2017) Clinical and immunological characteristics of autoimmune addison disease: a nationwide swedish multicenter study. J Clin Endocrinol Metab 102:379\u2013389","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1530\/EC-18-0418","volume":"8","author":"K Iqbal","year":"2019","unstructured":"Iqbal K, Halsby K, Murray RD, Carroll PV, Petermann R (2019) Glucocorticoid management of adrenal insufficiency in the United Kingdom: assessment using real-world data. Endocr Connect 8:20\u201331","journal-title":"Endocr Connect"},{"key":"1386_CR19","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1210\/jc.2018-02298","volume":"104","author":"J Skov","year":"2019","unstructured":"Skov J, Sundstr\u00f6m A, Ludvigsson JF, K\u00e4mpe O, Bensing S (2019) Sex-specific risk of cardiovascular disease in autoimmune Addison disease\u2014a population-based cohort study. J Clin Endocrinol Metab 104:2031\u20132040","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR20","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1210\/jc.2015-1710","volume":"101","author":"SR Bornstein","year":"2016","unstructured":"Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A et al (2016) Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:364\u2013389","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR21","doi-asserted-by":"publisher","first-page":"3888","DOI":"10.1210\/jc.2016-2118","volume":"101","author":"M Fleseriu","year":"2016","unstructured":"Fleseriu M, Hashim IA, Karavitaki N, Melmed S, Murad MH et al (2016) Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 101:3888\u20133921","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR22","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/cen.13267","volume":"86","author":"RD Murray","year":"2017","unstructured":"Murray RD, Ekman B, Uddin S, Marelli C, Quinkler M et al (2017) Management of glucocorticoid replacement in adrenal insufficiency shows notable heterogeneity\u2014data from the EU-AIR. Clin Endocrinol (Oxf) 86:340\u2013346","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1386_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1472-6823-12-8","volume":"12","author":"M Forss","year":"2012","unstructured":"Forss M, Batcheller G, Skrtic S, Johannsson G (2012) Current practice of glucocorticoid replacement therapy and patient-perceived health outcomes in adrenal insufficiency\u2014a worldwide patient survey. BMC Endocr Disord 12:8","journal-title":"BMC Endocr Disord"},{"key":"1386_CR24","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/B978-0-444-59602-4.00026-5","volume":"124","author":"FM Swords","year":"2014","unstructured":"Swords FM (2014) Uncertainties in endocrine substitution therapy for central hypocortisolism. Handb Clin Neurol 124:387\u2013396","journal-title":"Handb Clin Neurol"},{"key":"1386_CR25","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ando.2017.10.007","volume":"78","author":"F Castinetti","year":"2017","unstructured":"Castinetti F, Guignat L, Bouvattier C, Samara-Boustani D, Reznik Y (2017) Group 4: Replacement therapy for adrenal insufficiency. Ann Endocrinol (Paris) 78:525\u2013534","journal-title":"Ann Endocrinol (Paris)"},{"key":"1386_CR26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1530\/EJE-13-0528","volume":"169","author":"C Betterle","year":"2013","unstructured":"Betterle C, Scarpa R, Garelli S, Morlin L, Lazzarotto F et al (2013) Addison's disease: a survey on 633 patients in Padova. Eur J Endocrinol 169:773\u2013784","journal-title":"Eur J Endocrinol"},{"key":"1386_CR27","doi-asserted-by":"crossref","unstructured":"Isidori AM, Arnaldi G, Boscaro M, Falorni A, Giordano C, et al., (2019) Towards the tailoring of glucocorticoid replacement in adrenal insufficiency: the Italian Society of Endocrinology Expert Opinion. J Endocrinol Invest.","DOI":"10.1007\/s40618-019-01146-y"},{"key":"1386_CR28","first-page":"4172","volume":"84","author":"JS Moore","year":"1999","unstructured":"Moore JS, Monson JP, Kaltsas G, Putignano P, Wood PJ et al (1999) Modulation of 11beta-hydroxysteroid dehydrogenase isozymes by growth hormone and insulin-like growth factor: in vivo and in vitro studies. J Clin Endocrinol Metab 84:4172\u20134177","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR29","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1046\/j.1365-2265.2003.01894.x","volume":"59","author":"FM Swords","year":"2003","unstructured":"Swords FM, Carroll PV, Kisalu J, Wood PJ, Taylor NF et al (2003) The effects of growth hormone deficiency and replacement on glucocorticoid exposure in hypopituitary patients on cortisone acetate and hydrocortisone replacement. Clin Endocrinol (Oxf) 59:613\u2013620","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1386_CR30","doi-asserted-by":"publisher","first-page":"3954","DOI":"10.1210\/jc.2006-0524","volume":"91","author":"H Filipsson","year":"2006","unstructured":"Filipsson H, Monson JP, Koltowska-H\u00e4ggstr\u00f6m M, Mattsson A, Johannsson G (2006) The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients. J Clin Endocrinol Metab 91:3954\u20133961","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR31","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1530\/EJE-14-1114","volume":"172","author":"M Quinkler","year":"2015","unstructured":"Quinkler M, Miodini Nilsen R, Zopf K, Ventz M, \u00d8ksnes M (2015) Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur J Endocrinol 172:619\u2013626","journal-title":"Eur J Endocrinol"},{"key":"1386_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1530\/EJE-14-0327","volume":"171","author":"AG Nilsson","year":"2014","unstructured":"Nilsson AG, Marelli C, Fitts D, Bergthorsdottir R, Burman P et al (2014) Prospective evaluation of long-term safety of dual-release hydrocortisone replacement administered once daily in patients with adrenal insufficiency. Eur J Endocrinol 171:369\u2013377","journal-title":"Eur J Endocrinol"},{"key":"1386_CR33","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1515\/cclm-2018-0824","volume":"57","author":"F Ceccato","year":"2019","unstructured":"Ceccato F, Scaroni C (2019) Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment. Clin Chem Lab Med 57:1125\u20131135","journal-title":"Clin Chem Lab Med"},{"key":"1386_CR34","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1530\/EC-17-0368","volume":"7","author":"LM Mongio\u00ec","year":"2018","unstructured":"Mongio\u00ec LM, Condorelli RA, La Vignera S, Calogero AE (2018) Dual-release hydrocortisone treatment: glycometabolic profile and health-related quality of life. Endocr Connect 7:211\u2013219","journal-title":"Endocr Connect"},{"key":"1386_CR35","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/cen.14006","volume":"91","author":"A Vulto","year":"2019","unstructured":"Vulto A, Bergthorsdottir R, van Faassen M, Kema IP, Johannsson G et al (2019) Residual endogenous corticosteroid production in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 91:383\u2013390","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1386_CR36","first-page":"501","volume":"36","author":"SA Lottenberg","year":"1998","unstructured":"Lottenberg SA, Giannella-Neto D, Derendorf H, Rocha M, Bosco A et al (1998) Effect of fat distribution on the pharmacokinetics of cortisol in obesity. Int J Clin Pharmacol Ther 36:501\u2013505","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1386_CR37","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1530\/EC-17-0160","volume":"6","author":"F Roelfsema","year":"2017","unstructured":"Roelfsema F, van Heemst D, Iranmanesh A, Takahashi P, Yang R et al (2017) Impact of age, sex and body mass index on cortisol secretion in 143 healthy adults. Endocr Connect 6:500\u2013509","journal-title":"Endocr Connect"},{"key":"1386_CR38","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1210\/jcem-72-1-39","volume":"72","author":"NV Esteban","year":"1991","unstructured":"Esteban NV, Loughlin T, Yergey AL, Zawadzki JK, Booth JD et al (1991) Daily cortisol production rate in man determined by stable isotope dilution\/mass spectrometry. J Clin Endocrinol Metab 72:39\u201345","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1530\/EJE-14-0397","volume":"171","author":"O Ragnarsson","year":"2014","unstructured":"Ragnarsson O, Mattsson AF, Monson JP, Filipsson Nystr\u00f6m H, \u00c5kerblad AC et al (2014) The relationship between glucocorticoid replacement and quality of life in 2737 hypopituitary patients. Eur J Endocrinol 171:571\u2013579","journal-title":"Eur J Endocrinol"},{"key":"1386_CR40","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3803\/EnM.2017.32.4.466","volume":"32","author":"AR Hong","year":"2017","unstructured":"Hong AR, Ryu OH, Kim SY, Kim SW, Korean Adrenal Gland, and Endocrine Hypertension Study Group KrES (2017) Characteristics of Korean patients with primary adrenal insufficiency: a registry-based nationwide survey in Korea. Endocrinol Metab (Seoul) 32:466\u2013474","journal-title":"Endocrinol Metab (Seoul)"},{"key":"1386_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1210\/jc.2017-01928","volume":"103","author":"D Esposito","year":"2018","unstructured":"Esposito D, Pasquali D, Johannsson G (2018) Primary adrenal insufficiency: managing mineralocorticoid replacement therapy. J Clin Endocrinol Metab 103:376\u2013387","journal-title":"J Clin Endocrinol Metab"},{"key":"1386_CR42","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1210\/jc.2016-2216","volume":"101","author":"J Werumeus Buning","year":"2016","unstructured":"Werumeus Buning J, van Faassen M, Brummelman P, Dullaart RP, van den Berg G et al (2016) Effects of hydrocortisone on the regulation of blood pressure: results from a randomized controlled trial. J Clin Endocrinol Metab 101:3691\u20133699","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01386-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-020-01386-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-020-01386-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T23:12:03Z","timestamp":1628550723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-020-01386-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,10]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["1386"],"URL":"https:\/\/doi.org\/10.1007\/s40618-020-01386-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,10]]},"assertion":[{"value":"16 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SP, AR, IT, SC, FF, MR, GB, MP, FD, AP, AL, AA, and MT have nothing to declare. GR is part of the advisory board of Shire-Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethical committees of San Luigi Gonzaga Hospital\u2014University of Turin, Santa Croce e Carle Hospital of Cuneo, Gaetano Martino Hospital\u2014University of Messina, and it was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The need to obtain informed consent from the study participants was waived due to the study's retrospective and observational nature.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}